HOME >> BIOLOGY >> NEWS
Aggressive therapy best for certain AML patients

-looking chromosomes. These cells lack the microscopic chromosome damage that guide therapy.

In 1994, however, a team of researchers that included Bloomfield discovered the MLL-PTD mutation in these patients. It was the first clinically useful marker to be identified in cases of AML with normal-looking chromosomes, and it was found to predict a short remission and poor response to therapy. About 8 percent of AML patients with normal-looking chromosomes have the mutation.

Studies done eight to 10 years ago showed that nearly 100 percent of these patients relapsed and died within two years, says first author Susan P. Whitman, a research scientist at Ohio State's Comprehensive Cancer Center.

This retrospective study set out to learn whether aggressive therapy provided through two CALGB clinical trials benefits patients with the mutation. It evaluated 238 people aged 18 to 59 with AML and normal-looking chromosomes. Of these, 24 (10 percent) had the MLL-PTD mutation.

All patients received an initial aggressive chemotherapy regimen (i.e., induction therapy) to induce remission. Those who achieved remission then received further aggressive therapy (i.e., consolidation therapy), usually an autologous stem cell transplant, with a few receiving intensive chemotherapy.

Of the 24 patients with the mutation, 22 had a complete remission. Of those, 13 relapsed within 1.4 years, but nine (41 percent) remained in remission when the study ended, with disease-free periods ranging from two to almost eight years.

We believe that the use of aggressive consolidation therapy may have contributed to the reduced number of early relapses in these patients, Bloomfield says.

We still must do larger studies to confirm these findings, to better understand this disease and to develop curative targeted therapies.


'"/>

Contact: Eileen Scahill
Eileen.Scahill@osumc.edu
614-293-2092
Ohio State University
1-Aug-2007


Page: 1 2

Related biology news :

1. Aggressive subtype of breast cancer displays misbehavior of X chromosomes
2. Aggressive aquatic species invading Great Lakes
3. Testosterone replacement therapy: How safe for aging men?
4. Progesterone therapy and preterm birth: More evidence helps identify women who can benefit
5. Under magnetic force, nanoparticles may deliver gene therapy
6. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
7. Stem cell therapy rescues motor neurons in ALS model
8. Study identifies new gene therapy tools for inherited blindness
9. Breast cancer and hormone therapy -- A looking-glass mirror?
10. Radiation therapy combined with microsurgery shows promise for curing injured spinal cord
11. Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2020)... KEYNES, England (PRWEB) , ... June 23, 2020 ... ... in Africa supporting sustainable healthcare, and Renovagen Ltd, a UK supplier and manufacturer ... response project to support testing operations in the fight against the COVID-19 pandemic ...
(Date:6/23/2020)... ... June 23, 2020 , ... Rigaku ... the next event in a series of TOPIQ webinars, which will cover the ... webinars was developed in response to social distancing measures that resulted in postponements ...
(Date:6/19/2020)... ... June 16, 2020 , ... The director of stem ... that if the stem cell medicine and pharmaceutical industries have easier access to stem ... So, starting July 5 of this year, Independence Day weekend in the U.S., Asymmetrex ...
Breaking Biology News(10 mins):
(Date:8/15/2020)... ... August 13, 2020 , ... Inc. magazine today revealed that ... ranking of the nation’s fastest-growing private companies. The list represents a unique look ... small businesses. Intuit, Zappos, Under Armour, Microsoft, Patagonia, and many other well-known names ...
(Date:8/3/2020)... , ... August 03, 2020 , ... ... today announced Jim Corrigan, President and CEO has been named one of the ... cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how they ...
(Date:7/31/2020)... ... July 29, 2020 , ... Anomet Products ... three different materials for use with CRM, neurostimulation, vascular, and related devices. , ... meet specific design requirements, performance, and cost criteria; especially where solid wire is ...
(Date:7/22/2020)... ... July 22, 2020 , ... Join experts from Reed Tech ... Regulatory Solutions, in a one hour live webinar on Thursday, August 13, ... China for drugs and medical devices. Specifically, for medical devices, the NMPA has departments ...
Breaking Biology Technology:
Cached News: